KOSDAQMachinery460940

P&S Robotics

₩5,600▲ 14.40%2026-11-18 close
Market Cap
₩75.3B
Turnover
₩17.8B
Volume
3.3M
Shares out.
13.5M
PER
43.7×
PBR
1.5×
EPS
₩111
Dividend Yield
0.82%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩40 per share · Prices as of the 2026-11-18 close

01

Report overview

Back in Quarterly Profit, Cash Flow in Focus

P&S Robotics returned to operating profit in the third quarter of 2026, while the 2025 operating cash outflow and rising receivables remain open questions.

  1. 1

    Annual revenue rose from KRW 6.01 billion in 2023 to KRW 7.64 billion in 2025, but operating profit fell 38.0% to KRW 1 billion in 2025 from KRW 1.62 billion a year earlier.

  2. 2

    Third-quarter 2026 revenue reached KRW 2.29 billion, up 191.9% year on year, and operating profit of KRW 388 million marked a swing to profit. Net income attributable to controlling shareholders was KRW 52.95 million, down 75.7% from the prior quarter.

  3. 3

    Operating cash flow turned to -KRW 1.58 billion in 2025, and media reports said receivables rose from KRW 2.06 billion to KRW 4.77 billion.

  4. 4

    The business is export-heavy: the export share was 85.1% in the third quarter of 2024, and the company holds export contracts with 15 countries.

  5. 5

    As of October 2026, the price-to-book ratio and dividend yield sat below the medical equipment industry average, while the share price still carries a premium over book value.

02

Business structure

P&S Robotics is a rehabilitation robot company founded in 2003, and the company states that it developed and commercialized Korea's first walking-rehabilitation robot system in 2011. Its flagship product is the Walkbot, a gait-rehabilitation robot supplied to medical institutions under a B2B model.

The company listed on KOSDAQ in July 2024. It says it has developed around 300 core robotics technologies, including humanoid, multi-joint, haptic and robot joint reducer technologies, and it sees room to extend them into upper-limb rehabilitation and wearable robots.

Upper-limb rehabilitation robots have been reported as new products, and the shoulder rehabilitation robot Healerbot was shown at the MEDICA exhibition in Germany. Upper-limb products are planned to use the distribution network built for the lower-limb robot.

Overseas sales dominate the mix: the export share was 85.1% in the third quarter of 2024, and the Russian share was reported at 25%. The Walkbot holds CE marking from 2013, FDA clearance from 2015, and EU MDR certification obtained in 2023.

Kiwoom Securities pointed to an export-related revenue share of 93.7% on a cumulative basis through the third quarter of 2025. Revenue is recognized only after products reach customers and are assembled, which tends to concentrate recognition in the fourth quarter. Analysts note that three companies, including P&S Robotics, compete in the domestic market.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩800M-₩800M−104.3%
2025Q4———
2026Q1₩900M-₩400M−38.3%
2026Q2₩1.7B-₩500M−26.5%
2026Q3₩2.3B₩400M16.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩6B₩1.3B₩1.4B22.0%18.3%19.1%
2024₩7.1B₩1.6B₩2.3B22.8%5.8%3.4%
2025₩7.6B₩1B₩2.7B13.1%6.4%4.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue rose from KRW 6.01 billion in 2023 to KRW 7.11 billion in 2024, an 18.2% increase, and then to KRW 7.64 billion in 2025, a 7.5% increase, marking two consecutive years of growth from 2024 through 2025. Of the 2023 to 2025 period, 2025 was the largest year for revenue and 2023 the smallest.

Operating profit grew from KRW 1.32 billion in 2023 to KRW 1.62 billion in 2024, up 22.5%, then fell 38.0% to KRW 1 billion in 2025, which makes 2025 the smallest year in the period.

The operating margin moved from 22.0% in 2023 and 22.8% in 2024 to 13.1% in 2025, so profitability weakened even as revenue grew, which suggests development spending weighed on margins.

The company attributed the 2025 change mainly to higher R&D expenses and a temporary drop in operating profit caused by the timing of revenue recognition.

Net income attributable to controlling shareholders rose from KRW 1.41 billion in 2023 to KRW 2.32 billion in 2024, up 64.7%, and then to KRW 2.75 billion in 2025, up 18.4%, marking two consecutive years of growth from 2024 through 2025.

In 2025 that figure exceeded operating profit, which suggests non-operating items added to earnings. Net income including non-controlling interests was also KRW 2.75 billion in 2025.

Operating cash flow moved the other way: it was KRW 807 million in 2023 and KRW 1.21 billion in 2024, then turned to -KRW 1.58 billion in 2025, and media reports said receivables rose from KRW 2.06 billion to KRW 4.77 billion.

In the third quarter of 2025, revenue was KRW 784 million, with an operating loss of KRW 818 million and a net loss attributable to controlling shareholders of KRW 156 million, and the company said prototype and exhibition costs were booked in selling and administrative expenses that quarter.

The first quarter of 2026 recorded revenue of KRW 932 million, an operating loss of KRW 357 million and a net loss attributable to controlling shareholders of KRW 57.58 million.

In the second quarter of 2026, revenue rose to KRW 1.73 billion, up 85.4% from the prior quarter, while the operating loss widened to KRW 458 million, and net income attributable to controlling shareholders swung to KRW 218 million.

In the third quarter of 2026, revenue reached KRW 2.29 billion, up 32.4% from the prior quarter and up 191.9% year on year, and operating profit was KRW 388 million, a swing to profit from a year earlier, but net income attributable to controlling shareholders fell to KRW 52.95 million, down 75.7% from the prior quarter.

Over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, net income attributable to controlling shareholders totaled KRW 1.5 billion.

05

Industry analysis

Demand for rehabilitation robots is supported by structural factors such as an aging population and a shortage of therapists. Korea Investment & Securities researchers said in a 2025 report that accelerating population aging and the shortage of therapists were expected to persist for some time.

A December 2025 report by Asia Economy cited a securities analyst projecting that the rehabilitation robot market would grow at an annual rate of 27.2%, but that is a projection from the time of publication and should be rechecked against the original report.

In overseas markets, certifications and distribution networks act as entry barriers, and P&S Robotics reportedly holds 19 certifications and 42 patents while maintaining export contracts with 15 countries.

The domestic market has three competing companies, and Kiwoom Securities described the company's domestic performance as relatively weak.

Listed robotics peers such as Doosan Robotics, Rainbow Robotics and Robotis are centered on industrial and collaborative robots, so their business structures differ from medical rehabilitation devices.

The share price is also influenced by thematic flows in robotics stocks, and a November 2026 report said the stock rose strongly alongside a broad rally in robotics shares. Because revenue recognition concentrates in the fourth quarter, quarterly results are subject to seasonality.

06

Outlook

The confirmed business milestones are the mass-production preparation for the upper-limb rehabilitation robot and supply contract disclosures. After the launch, the company was reported to have entered full mass-production preparation, and analysts have described the upper-limb line as a new growth engine.

Single-sales and supply contract disclosures were filed on July 30, 2026, followed by a correction filing on October 21, 2026. Contract size, duration and counterparties need to be confirmed in the original filings.

Quarterly revenue has risen in the second and third quarters of 2026 after the first-quarter low, which can be read as an early sign of order growth.

Because revenue recognition tends to concentrate in the fourth quarter, the next checkpoint is how fourth-quarter 2026 revenue and operating profit are reflected in full-year results. Whether the annual operating margin recovers from 13.1% in 2025 is also a key item.

Since operating cash flow was negative in 2025, the collection of receivables and any turn in operating cash flow should be tracked together. Export expansion supported by overseas certifications and patents, and changes in the weight of specific countries including Russia, can also be followed through disclosures. Full-year confirmed figures will first appear in the 2026 annual report.

07

Valuation

PER
43.7×
PBR
1.5×
ROE
3.6%
EPS
₩111
BPS
₩3,168
Dividend per share
₩40

Valuation should be read through both earnings-based and book-value-based multiples. Net income attributable to controlling shareholders over the last four quarters totals KRW 1.5 billion, so earnings-based multiples move sharply with quarterly results.

On a book-value basis, total equity was KRW 43.2 billion at the end of 2025, all attributable to controlling shareholders, and total liabilities were a small KRW 1.86 billion. In this structure, the share price sits at a premium over book value.

As of October 2026, the price-to-book ratio was below the medical equipment industry average. The dividend yield was also below the industry average at that time. At the regular shareholders' meeting on March 27, 2026, the company approved a year-end cash dividend.

Because earnings are still small, a single quarter's profit and loss mix can change multiples substantially, so the reading should be revisited once full-year confirmed results are published.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Export base and accumulated certifications

The export share was 85.1% in the third quarter of 2024, and the company was reported to hold export contracts with 15 countries. The Walkbot holds CE and FDA clearances, and EU MDR certification was obtained in 2023. These certifications and patents can serve as a base for wider overseas distribution.

Recovery in quarterly results

Net income attributable to controlling shareholders turned positive in the second quarter of 2026, and operating profit turned to KRW 388 million in the third quarter. Revenue has risen for two consecutive quarters since the first-quarter 2026 low, and third-quarter revenue was up 191.9% year on year. The move from losses to profit is a supportive factor.

A nearly debt-free balance sheet

The debt-to-equity ratio was 4.3% at the end of 2025, and total liabilities were a small KRW 1.86 billion. Media reports said borrowings stood at zero as of the third quarter of 2025. This financial capacity lets the company pursue R&D and upper-limb mass-production preparation at the same time.

09

Bear factors

Lower operating profit and margin

Operating profit in 2025 was KRW 1 billion, down 38.0% year on year, and the operating margin fell to 13.1% from 22.8% in 2024. The company cited higher R&D expenses and the timing of revenue recognition, but whether this cost structure is temporary has yet to be confirmed in full-year results. If margins do not recover, concerns about earnings capacity could persist.

Cash flow and receivables pressure

Operating cash flow turned to -KRW 1.58 billion in 2025. Media reports said receivables rose from KRW 2.06 billion to KRW 4.77 billion over the same period, and cash and equivalents also declined.

Operating cash turning negative even with positive operating profit can be read as a sign that earnings are not converting into cash smoothly.

Volatility in quarterly earnings

Net income attributable to controlling shareholders in the third quarter of 2026 was KRW 52.95 million, down 75.7% from the prior quarter. Revenue is recognized after assembly at the customer site, which tends to concentrate it in the fourth quarter.

If profit and loss swing sharply from quarter to quarter even after the return to profit, the sustainability of earnings is harder to judge.

10

Risk factors

Export dependence and geopolitical exposure

The export share was 85.1% in the third quarter of 2024, and the Russian share was reported at 25%. Changes in policy, exchange rates or payment conditions in a given country could directly affect revenue. The cost of maintaining overseas certifications and responding to local regulation also remains a long-term risk.

Share price volatility and thematic flows

The share price rose 29.95% in a single session on October 28, 2026, showing large swings. A November 2026 report said the stock was strong amid a broad rally in robotics shares. Because thematic flows can move the share price independently of earnings, price drivers and earnings drivers should be separated.

Revenue timing and cash collection

Revenue is recognized only after products reach the customer and are assembled, so quarterly results can vary widely with timing. Revenue grew in 2025 while operating cash flow was negative, and media reports said receivables increased. Delays in collection or changes in payment terms cannot be ruled out.

11

What to watch next

  1. Mid-February 2027 (expected)

    Preliminary full-year 2026 results. Based on the precedent of the February 11, 2026 preliminary filing, a similar timing is expected. Watch whether the operating margin recovers from 13.1% in 2025 and whether operating cash flow turns positive.

  2. Late March 2027 (annual report filing deadline)

    Confirmed financial figures in the 2026 annual report. Check full-year revenue, fourth-quarter figures, receivables collection and the composition of non-operating items.

  3. March 2027 regular shareholders' meeting (expected)

    Dividend proposal for fiscal 2026. The March 27, 2026 meeting approved a year-end cash dividend, so whether a similar proposal returns in the same season should be checked.

  4. Ongoing (when supply contract disclosures are filed)

    Single-sales and supply contract disclosures. Check whether further contracts follow the July 30, 2026 filing and the October 21, 2026 correction, and how contract size and duration connect to quarterly revenue.

12

Overall view

P&S Robotics is a medical robotics company centered on gait-rehabilitation robots, with a large share of revenue from overseas. From 2023 to 2025, revenue rose from KRW 6.01 billion to KRW 7.64 billion, and net income attributable to controlling shareholders rose from KRW 1.41 billion to KRW 2.75 billion.

Operating profit, however, fell 38.0% to KRW 1 billion in 2025, and the operating margin dropped to 13.1%. In 2026, quarterly revenue rose for two consecutive quarters after the first-quarter low, and operating profit turned to a profit in the third quarter.

Supportive factors include the export base, the certifications and a balance sheet without borrowings, while the negative factors are the 2025 operating cash outflow, rising receivables and wide swings in quarterly earnings.

Net income attributable to controlling shareholders fell from the prior quarter in the third quarter of 2026, so whether the return to profit holds needs to be confirmed.

The next checkpoints are the preliminary full-year 2026 results, the confirmed figures and cash flows in the 2026 annual report, and supply contract disclosures. This report is for information only and does not include a buy or sell opinion or a target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. jobkorea.co.kr
  2. innoforest.co.kr
  3. walkbot.co.kr
  4. widedaily.com
  5. view.asiae.co.kr
  6. dealsite.co.kr
  7. catch.co.kr
  8. etoday.co.kr
  9. m.newsprime.co.kr
  10. comp.fnguide.com
  11. alphasquare.co.kr
  12. news.nate.com
  13. vegannews.co.kr
  14. job-post.co.kr
  15. dailyan.com
  16. etoday.co.kr
  17. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis